Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception

Biochemical Pharmacology

Volumn 53, Issue 10, 1997, Pages 1451-1457

  Ouellet, Daniele M C ^a,b   Pollack, Gary M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b MDS Inc   (Canada)

Author keywords

Antinociception; Morphine; Morphine 3 glucuronide; Pharmacodynamics; Pharmacokinetics; Tolerance

Indexed keywords

MORPHINE; MORPHINE 3 GLUCURONIDE; NALORPHINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TOLERANCE; INTRAVENOUS DRUG ADMINISTRATION; LATENT PERIOD; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; TAIL FLICK TEST;

ANIMALS; DRUG TOLERANCE; HALF-LIFE; MALE; MODELS, BIOLOGICAL; MORPHINE; MORPHINE DERIVATIVES; NOCICEPTORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030739475     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00086-5     Document Type: Article

References (23)

1. Jaffe JH and Martin ER, Opioid analgesics and antagonists. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics (Eds. Oilman AG, Rail TW, Nies AS and Taylor P), 8th Edn, pp. 485-522. Pergamon Press, New York, 1990.
2. Säwe J, High-dose morphine and methadone in cancer patients: Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet 11: 87-106, 1986.
3. Säwe J, Svensson JO and Rane A, Morphine metabolism in cancer patients on increasing oral doses - No evidence for autoinduction or dose-dependence. Br J Clin Pharmacol 16: 85-93, 1983.
4. Carrupt P-A, Testa B, Bechalany A, El Tayar N, Descas P and Perrissoud D, Morphine-6-glucuronide and morphine-3-glucuronide as molecular chameleons with unexpected lipophilicity. J Med Chem 34: 1272-1275, 1991.
5. Yoshimura H, Ida S, Oguri K and Tsukamoto H, Biochemical basis for analgesic activity of morphine-6-glucuronide-I. Penetration of morphine-6-glucuronide in the brain of rats. Biochem Pharmacol 22: 1423-1430, 1973.
6. Hand CW, Blunnie WP, Claffey LP, McShane AJ, McQuay HJ and Moore HJ, Potential analgesic contribution from morphine-6-glucuronide in CSF. Lancet ii: 1207-1208, 1987.
7. Paul D, Standifer KM, Inturrisi CE and Pasternak GW, Pharmacological characterization of morphine-6-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 251: 477-483, 1990.
8. Pasternak GW, Bodnar RJ, Clark JA and Inturrisi CE, Morphine-6-glucuronide, a potent mu agonist. Life Sci 41: 2845-2849, 1987.
9. Ekblom M, Gårdmark M and Hammarlund-Udenaes M, Pharmacokinetics and pharmacodynamics of morphine-3-glucuronide in rats and its influence on the antinociceptive effect of morphine. Biopharm Drug Dispos 14: 1-11, 1993.
10. Smith MT, Watt JA and Cramond T, Morphine-3-glucuronide - A potent antagonist of morphine analgesia. Life Sci 47: 579-585, 1990.
11. Gong Q-L, Hedner J, Björkman R and Hedner T, Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 48: 249-255, 1992.
12. Quellet DM-C and Pollack GM, A pharmacokinetic-pharmacodynamic model of tolerance to morphine analgesia during infusion in rats. J Pharmacokinet Biopharm 23: 531-549, 1995.
13. Kissin I, Brown PT, Robinson A and Bradley EL Jr, Acute tolerance in morphine analgesia: Continuous infusion and single injection in rats. Anesthesiology 74: 166-171, 1991.
14. Kuo CK, Hanioka N, Hoshikawa Y, Oguri K and Yoshimura H, Species difference of site-selective glucuronidation of morphine. J Pharmacobiodyn 14: 187-193, 1991.
15. Lawrence AJ, Michalkiewicz A, Morley JS, MacKinnon K and Billington D, Differential inhibition of hepatic morphine UDP-glucuronosyltransferases by metal ions. Biochem Pharmacol 43: 2335-2340, 1992.
16. Quellet DM-C and Pollack GM, Biliary excretion and enterohepatic recirculation of morphine-3-glucuronide in rats. Drug Metab Dispos 23: 478-484, 1995.
17. Sheiner LB, Stanski DR, Vozeh S, Miller RD and Ham J, Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin Pharmacol Ther 25: 358-371, 1979.
18. Hewett K, Dickenson AH and McQuay HJ, Lack of effect of morphine-3-glucuronide on the spinal antinociceptive actions of morphine in the rat: An electrophysiological study. Pain 53: 59-63, 1993.
19. Yaksh TL, Harty GJ and Onofrio BM, High doses of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: Clinical and theoretic implications. Anesthesiology 64: 590-597, 1986.
20. Lipkowski AW, Carr DB, Langlade A, Osgood PF and Szyfelbein SK, Morphine-3-glucuronide: Silent regulator of morphine actions. Life Sci 55: 149-154, 1994.
21. Smith GD and Smith MT, Morphine-3-glucuronide: Evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat. Pain 62: 51-60, 1995.
22. Horton TL and Pollack GM, Enterohepatic recirculation and renal metabolism of morphine in the rat. J Pharm Sci 80: 1147-1152, 1991.
23. Dahlström BE and Paalzow LK, Pharmacokinetic interpretation of the enterohepatic recirculation and first-pass elimination of morphine in the rat. J Pharmacokinet Biopharm 6: 505-519, 1978.